ODM-203 is primarily explored for its potential in cancer therapy, specifically targeting fibroblast growth factor receptor (FGFR) signaling pathways. Its application lies in inhibiting FGFR activity, which is often dysregulated in various cancers, such as bladder, breast, and lung cancer. By blocking these receptors, it aims to suppress tumor growth and progression. Research is ongoing to evaluate its efficacy and safety in clinical trials, particularly for patients with FGFR-driven malignancies. Its development represents a targeted approach to cancer treatment, offering a potential therapeutic option for resistant or advanced cases.